Eli Lilly opposes Trump MFN drug pricing law, CEO Ricks says

Dave Ricks, CEO of Eli Lilly, speaks in the Oval Office during an event about weight loss medications at the White House in Washington on November 6, 2025.
Andrew Caballero-Reynolds | AFP | Getty Images
Eli Lilly CEO Dave Ricks said in an interview with CNBC that he opposes the White House’s effort to legislate “most favored nation” drug pricing.
Lilly is one of more than a dozen drugmakers that signed deals with the Trump administration last year agreeing to charge similar prices for prescription drugs in the United States as in other rich countries. President Donald Trump has long complained that Americans pay high prices to subsidize low drug prices in the rest of the world.
The pharmaceutical industry felt the agreements would assuage these concerns and thwart attempts to price the law as “most favored nation.” But the White House has pushed Congress to adjust elements of the agreements in recent months. However, the draft text was not made public management said is trying to get pharmaceutical companies to support this effort.
Ricks said Lilly didn’t support it.
“When you bring it into the congressional process, what goes in is not what comes out,” Ricks said. “And I think we’re seeing a lot of people today who would rather lower prices and not worry about whether we’ll have new drugs tomorrow, not worry about whether America will have a strong pharmaceutical industry and whether we’ll be able to do research in this country. And I worry about those issues, so I don’t think it’s a great idea, and we’ve been pretty clear with the administration and congressional leaders about that.”
Ricks said he thought the Trump administration and leadership on the Hill were listening to the company’s concerns, but Lilly “is going to use every tool we have to combat bad policy, and we think it’s going to be bad policy.”


